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Abstract
Background:  Only a small number of previous efforts to describe the experiences of
organizations that produce clinical practice guidelines (CPGs), undertake health technology
assessments (HTAs), or directly support the use of research evidence in developing health policy
(i.e., government support units, or GSUs) have relied on interviews and then only with HTA
agencies. Interviews offer the potential for capturing experiences in great depth, particularly the
experiences of organizations that may be under-represented in surveys.
Methods:  We purposively sampled organizations from among those who completed a
questionnaire in the first phase of our three-phase study, developed and piloted a semi-structured
interview guide, and conducted the interviews by telephone, audio-taped them, and took notes
simultaneously. Binary or categorical responses to more structured questions were counted when
possible. Themes were identified from among responses to semi-structured questions using a
constant comparative method of analysis. Illustrative quotations were identified to supplement the
narrative description of the themes.
Results: We interviewed the director (or his or her nominee) in 25 organizations, of which 12
were GSUs. Using rigorous methods that are systematic and transparent (sometimes shortened to
'being evidence-based') was the most commonly cited strength among all organizations. GSUs more
consistently described their close links with policymakers as a strength, whereas organizations
producing CPGs, HTAs, or both had conflicting viewpoints about such close links. With few
exceptions, all types of organizations tended to focus largely on weaknesses in implementation,
rather than strengths. The advice offered to those trying to establish similar organizations include:
1) collaborate with other organizations; 2) establish strong links with policymakers and
stakeholders; 3) be independent and manage conflicts of interest; 4) build capacity; 5) use good
methods and be transparent; 6) start small and address important questions; and 7) be attentive to
implementation considerations. The advice offered to the World Health Organization (WHO) and
other international organizations and networks was to foster collaborations across organizations.
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Conclusion: The findings from our interview study, the most broadly based of its kind, extend to
both CPG-producing organizations and GSUs the applicability of the messages arising from
previous interview studies of HTA agencies, such as to collaborate with other organizations and to
be attentive to implementation considerations. Our interview study also provides a rich description
of organizations supporting the use of research evidence, which can be drawn upon by those
establishing or leading similar organizations in LMICs.
Background
Organizations have been established in many countries
and internationally to support the use of research evi-
dence in developing health policy. These include organi-
zations that produce clinical practice guidelines (CPGs),
health technology assessment (HTA) agencies, and organ-
izations that directly support the use of research evidence
in developing health policy on an international, national,
and state or provincial level (i.e., government support
units, or GSUs). As we argued in the introductory article
in the series, a review of the experiences of such organiza-
tions, especially those based in low- and middle-income
countries (LMICs) and that are in some way successful or
innovative, can reduce the need to 'reinvent the wheel'
and inform decisions about how best to organize support
for evidence-informed health policy development proc-
esses in LMICs (Table 1) [1]. We described in the second
article in the series the methods and findings from the first
(survey) phase of our three-phase, multi-method study
[2,3].
We focus here on describing the methods and findings
from the study's second phase. In this phase, we inter-
viewed the senior staff member of a purposively sampled
sub-group of organizations around the world, and espe-
cially in LMICs, that are in some way successful or inno-
vative in supporting the use of research evidence in the
development of CPGs, HTAs, and health policy. Previous
efforts to describe the experiences of such organizations
have relied primarily on surveys [4-16], which offer the
potential for capturing a tremendous breadth of experi-
ences. Only a small number of efforts have relied on inter-
views and then only with HTA agencies (or in one case
with individuals associated with both HTA and health-
services research), not with CPG-producing organizations
or GSUs [14,17-20]. Interviews offer the potential for cap-
turing experiences in far more depth, particularly the
experiences of organizations that may be under-repre-
sented in surveys, such as GSUs, organizations that are in
some way successful or innovative, and organizations that
are based in LMICs. In the next and final article in the
series, we provide more detail about the methods and
findings from the third (case descriptions) phase of the
study [21].
Methods
Study sample
We purposively sampled organizations from among those
who completed a questionnaire based on the following
three criteria: 1) able to provide rich descriptions of their
processes and lessons learned; 2) particularly successful or
innovative in one or more of the seven domains covered
in the questionnaire; and 3) influential over time within
their own jurisdiction in supporting the use of research
evidence, or influential in the establishment or evolution
of similar organizations in other jurisdictions. The first
criterion was applied by one member of the study team
(RM) based on his reading of the completed question-
naires. The second and third criteria were applied by three
members of the study team (AO, JNL, RM) based on their
knowledge of and experience with these types of organiza-
tions.
Interview guide development and interviewing
We developed the first draft of the semi-structured inter-
view guide in parallel with the questionnaire as a mecha-
Table 1: Overview of the four-article series
[1] Synthesis of findings from the three-phase, multi-method study
[2] Survey of a senior staff member (the director or his or her nominee) of clinical practice guideline-producing organizations, 
HTA agencies, and government support units
This article Interview with the senior staff member of a purposively sampled sub-group of these three types of 
organizations, with an emphasis on those organizations that were particularly successful or innovative
[21] Case descriptions (based on site visits) of one or more organizations supporting the use of research evidence from among the 
cases described in the interviews and (once) other cases with which we were familiar, again with an emphasis on those 
organizations that were particularly successful or innovativeImplementation Science 2008, 3:55 http://www.implementationscience.com/content/3/1/55
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nism to augment questions that could not or could only
partially be addressed in the questionnaire. These 18 core
questions were followed by organization-specific ques-
tions that arose based on responses provided in the ques-
tionnaire and by cross-cutting questions that addressed
particular themes or hypotheses that emerged from the
survey or earlier interviews. One member of the study
team (RM) piloted the interview guide with four organiza-
tions, at least one of which was from each of the three cat-
egories. No significant changes were made after piloting.
See 'Additional file 1: Interview guide' for the interview
guide for units participating in the telephone interviews.
A request to be interviewed was sent by email to the direc-
tor (or another appropriate person) of each eligible organ-
ization and a date and time was set either through e-mail
or telephone calls. The same member of the study team
(RM) either conducted the interviews or supervised a
trained interviewer who conducted the interviews (LJ). All
interviews were conducted by telephone. Notes of all
interviews were taken simultaneously. All interviews were
audio-taped but only select interview segments were tran-
scribed verbatim.
Data management and analysis
Detailed summaries of each interview were prepared by
one member of the study team (RM) using both the audio
tapes and notes taken during the interviews, and these
detailed summaries were subsequently analyzed inde-
pendently by two members of the study team (AO, JL).
The detailed summaries were organized by question. Dur-
ing the analysis, the detailed summaries were first read
separately and supplemented, where necessary, by listen-
ing to part or all of the corresponding audio tapes. Binary
or categorical responses to more structured questions were
counted when possible. Themes were identified from
among responses to semi-structured questions using a
constant comparative method of analysis. Then question-
and theme-specific groupings of the detailed summaries
were developed and read, and the themes were modified
or amplified. Illustrative quotations were identified to
supplement the narrative description of the themes.
The principal investigator for the overall project (AO),
who is based in Norway, confirmed that, in accordance
with the country's Act on ethics and integrity in research,
this study did not require ethics approval from one of the
country's four regional committees for medical and health
research ethics. We obtained verbal consent to participate
in an interview. The nature of our request to participate in
an interview made clear that we would be profiling partic-
ular organizations. We did not in any way indicate that we
would treat interview data as confidential or that we
would safeguard participants' anonymity. Nevertheless,
we take care to ensure that no comments can be attributed
to a single individual even if the organization about which
an individual is speaking has been identified. We shared a
report on our findings with participants and none of them
requested any changes to how we present the data.
Results
The director (or his or her nominee) was interviewed in
25 organizations, including five organizations that pro-
duce CPGs, three that produce HTAs, five that produce
both CPGs and HTA, and 12 GSUs. Six organizations were
in Western Europe, five in North America, four in Asia,
three in Latin America, two each in Africa, Eastern Europe,
and the Middle East, and one in Australia. The organiza-
tions varied in size from a few people to 50. No organiza-
tions declined to participate in the interviews.
See additional file 2: Qualitative data for additional qual-
itative data, particularly illustrative quotations, from the
interviews. In the additional file, the text excised from this
article is bolded. In this article, the location from which
text was excised is denoted by a reference to the additional
file.
Mix of internally produced and externally commissioned 
work
The organizations employed a mix of models for produc-
ing outputs, with some undertaking some or all of the
work internally and others commissioning some or all of
the work externally. Seven organizations that produce
CPGs, HTAs, or both commissioned little or no work
(although one was soon to begin), five commissioned
some work (up to 25%), and one commissioned most of
its work. Six GSUs commissioned little or no work, four
commissioned some work, and the other two commis-
sioned about half their work.
Focus of activities
There was substantial variation in the number and type of
activities in which the organizations were involved. All
but one of the CPG-producing organizations were
involved only in producing CPGs, and the remaining
organization was involved in the education of both physi-
cians and consumers (patients and general public) as well.
Most (5 of 7) of the organizations that produce HTAs, or
both CPGs and HTAs, reported producing systematic
reviews as their major activity, while three reported under-
taking economic analyses and dissemination activities as
well. Other activities undertaken by organizations that
produce HTAs, or both CPGs and HTAs, included horizon
scanning, preparing policy papers, and conducting evalu-
ations (one each). GSUs reported involvement in a variety
of activities, including producing systematic reviews (n =
3), conducting policy analyses (n = 3), training and capac-
ity building (n = 3), producing CPGs (n = 2), conducting
evaluations (n = 2), conducting economic analyses (n =
2), conducting health systems research (n = 2), and under-Implementation Science 2008, 3:55 http://www.implementationscience.com/content/3/1/55
Page 4 of 10
(page number not for citation purposes)
taking consultations and communication activities (n =
2).
Priority-setting
All but one of the organizations producing CPGs, HTAs,
or both used informal methods for setting priorities,
whereas GSUs were more likely to respond to direct gov-
ernment requests. The exception among organizations
producing CPGs, HTAs, or both used a scoring system,
however, the organization's director added: 'Finally we
ask: Is the technology compelling or not compelling? We
find most decisions about prioritising are actually intui-
tive, so we have rolled this in. So, despite the scoring
sheet, the most important decision-making about priori-
ties for us is intuitive.' Among the organizations produc-
ing CPGs, HTAs, or both, one organization reported
responding to government requests and four reported
consulting with stakeholders. Other criteria that were con-
sidered include the frequency and severity of the problem,
potential for improvement and cost of achieving the
improvement, and avoiding duplication. About half of
these organizations reported making decisions internally,
and about the same proportion reported having a board
or advisory group that sets priorities. Turning now to the
GSUs, more than half of them (7 of 12) reported respond-
ing to requests for applications, two reported responding
to perceived policy needs, and one reported making deci-
sions through consultations involving staff and the Minis-
ter of Health. One had a board and one made five-year
plans based on an external review.
Methods used in producing a product or delivering a 
service
Organizations producing CPGs, HTAs, or both tended to
conduct or use systematic reviews (12 of 13) and to have
a manual that described the methods they use (11 of 13).
Far fewer convened groups to develop CPGs or HTAs (5 of
13), took equity considerations into account (1 of 13), or
had established a process for addressing conflicts of inter-
est (1 of 13). Two organizations described primarily using
secondary sources rather than conducting their own sys-
tematic reviews (see A.F.2). Only one of the five organiza-
tions that convened groups reported using a formal
consensus method (the RAND method), and two of the
other organizations described using some kind of interac-
tive process with either clinicians or policymakers (see
A.F.2). GSUs were less likely to conduct or use systematic
reviews (3 of 12) and to have a manual that described the
methods they use (4 of 12) and also more likely to report
using non-systematic methods to review the literature (3
of 12). Several GSUs reported conducting economic anal-
yses and using a variety of methods, including surveys,
epidemiological studies, and qualitative studies. One
GSU reported working with ethicists and addressing issues
of equity (see A.F.2).
Using rigorous methods that are systematic and transpar-
ent (sometimes shortened to 'being evidence-based') was
the most commonly cited strength among all organiza-
tions. Several organizations that produce CPGs, HTAs, or
both referred specifically to using 'Cochrane methods,'
one noted their use of a hierarchy of outcomes, and
another noted their use of the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
system (see A.F.2). The weaknesses noted by most of these
types of organizations were inadequate resources, more
specifically insufficient numbers of skilled staff and time,
together with using labour- and time-intensive processes
that limit the number and quality of CPGs and HTAs that
can be produced and updated. The GSUs, on the other
hand, identified a range of different types of research or
evaluation methods as additional strengths, including sys-
tematic reviews, measurement of health system perform-
ance, economic analyses, and surveys. Other strengths
noted by GSUs included: having a small organization that
can respond quickly, publishing drafts for public com-
ment, maintaining close links with policymakers, and
having independence and financial stability. The weak-
nesses that were identified by GSUs tended to be limita-
tions of the methods used or how the methods were
employed, including: not usually providing an exhaustive
literature search or critical appraisal, 'just a systematic
review often not being exactly what the audience wants,'
use of casual 'vote counting' instead of a more rigorous
approach to synthesizing research evidence, inaccuracies
in long-term forecasting, and limitations in how health
system performance is measured. GSUs also identified
inadequate human resources and time as weaknesses.
Recommendations or policy decisions related to their 
products
There was a great deal of variability both within and across
CPG-producing organizations, HTA-producing organiza-
tions, and GSUs in who makes recommendations or pol-
icy decisions related to their products and the processes
they use. For example, organizations producing CPGs,
HTAs, or both in some jurisdictions have full responsibil-
ity for making policy decisions, whereas in other jurisdic-
tions these decisions are made at the highest levels in the
Ministry of Health. Two GSUs based outside of govern-
ment acknowledged having little understanding of how
policy decisions are made. Other GSUs based outside of
government complained about the limited role of
research evidence in policy decisions (see A.F.2). In con-
trast, none of the directors based in government spoke of
the limited role of research evidence (see A.F.2). There was
also variability in the perceived strengths and weaknesses
of the processes that are used to make recommendations
or policy decisions. Several directors referred to the
explicit use of research evidence as a strength of the proc-
ess and the time or capacity needed to produce recom-Implementation Science 2008, 3:55 http://www.implementationscience.com/content/3/1/55
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mendations as a weakness (see A.F.2). GSUs more
consistently described their close links with policymakers
as a strength, particularly those GSUs based in govern-
ment, whereas organizations producing CPGs, HTAs, or
both had conflicting viewpoints about such close links
(see A.F.2). Two directors from organizations producing
CPGs, HTAs, or both referred to the split between synthe-
sizing the evidence and making a decision as a strength,
whereas another director identified the involvement of
stakeholders as a strength (see A.F.2). Another organiza-
tion identified involvement of stakeholders as a weakness
as well as a strength (see A.F.2). Two organizations pro-
ducing CPGs, HTAs, or both noted their lack of influence
as a weakness (see A.F.2). A lack of understanding of evi-
dence-informed decision-making and the need for more
education of and communication with policymakers was
also noted (see A.F.2) Organizations sometimes men-
tioned the media as both a strength and a weakness in
how recommendations or policy decisions related to their
products are made (see A.F.2).
Implementing recommendations or policy decisions 
related to their products
Most organizations argued that it is the clients who
requested a CPG or HTA, the minister of health or more
generally the department of health who is responsible for
implementing recommendations or policy decisions
related to their products (see A.F.2). Nearly all GSUs
viewed policy implementation as the government's
responsibility, although a couple of directors suggested
that individual physicians also have some responsibility.
Some organizations noted that responsibility for imple-
mentation is frequently spread among several organiza-
tions or that it is not clear who is responsible for
implementing policy decisions. All types of organizations
tended to focus largely on weaknesses in implementation,
with few exceptions (see A.F.2). One reason that was fre-
quently cited for this shortfall was the existence of multi-
ple actors and multiple decision-makers in
implementation processes that can be quite decentralized
(see A.F.2). Other reasons that were cited for inadequate
implementation included the general lack of formal proc-
esses for implementation, the specific challenges associ-
ated with guideline implementation (e.g., lack of financial
incentives for guideline adherence, practical difficulties in
engaging health professionals, particularly those in rural
areas), and the lack of funds to pay for effective (but
expensive) technologies (see A.F.2).
Approaches to personal communication with decision-
makers
While informal relationships with policymakers were
identified more frequently as important by GSUs (8 of 12)
than by organizations producing CPGs, HTAs, or both (4
of 13), nearly all of the organizations reported using per-
sonal communications with decision-makers, particularly
policymakers. For organizations producing CPGs, HTAs,
or both, informal relationships with health professionals
(8 of 13) and academics (5 of 13) were identified more
frequently as important to their organization than rela-
tionships with policymakers, and informal relationships
with other HTA organizations (e.g., Agency for Healthcare
Research and Quality, National Institute for Health and
Clinical Excellence, and Scottish Intercollegiate Guide-
lines Network) (n = 3), the Cochrane Collaboration (n =
2), International Network of Agencies for Health Technol-
ogy Assessment (n = 1), opinion leaders (n = 1), the
health services (n = 1), and the public (n = 1) were identi-
fied less frequently as important to their organization. For
GSUs, informal relationships with academics (n = 6) and
health professionals (n = 3) were identified less frequently
as important to their organization than relationships with
policymakers, and informal relationships with advocacy
organizations, non governmental organisations (NGOs),
funders, industry, an HTA organization, and World
Health Organisation (WHO) (one each) were identified
even less frequently as important to their organization.
Two organizations reported only having formal organiza-
tional relationships, and occasionally personal relation-
ships, but no informal organizational relationships.
While nearly all of the organizations reported using per-
sonal communications with decision-makers, a few
organizations reported having only ad hoc communica-
tion, communication through policy advisors only, or
only informal or indirect communication. A few of the
organizations considered themselves to be decision-mak-
ers, and several others were located within government.
Many of the organizations based within government
viewed their close links with policymakers as a strength
(see A.F.2). Organizations based outside of government
also viewed their close relationships with policymakers as
a strength (see A.F.2).
Advocates and critics
Many organizations, particularly those producing CPGs,
HTAs, or both, indicated that their strongest advocates
were health professionals, including frontline clinicians
and, especially, those who were involved in the organiza-
tions' activities (see A.F.2). However, physicians, particu-
larly older physicians, specialists, and experts could also
be among the most vocal critics (see A.F.2). The depart-
ment of health, as well as other regulatory bodies, health
insurers, and local health authorities or managers were
also frequently identified as strong advocates, both by
people working inside government and by those working
in organizations based outside of government (see A.F.2).
Other strong advocates that were identified included sat-
isfied clients, the mass media, speciality societies, and
other researchers. The last three were also seen as critics in
some jurisdictions or in some circumstances. The mostImplementation Science 2008, 3:55 http://www.implementationscience.com/content/3/1/55
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commonly identified critics were drug companies, partic-
ularly when their products were not recommended, and
more generally 'groups who don't like our findings; for
example, manufacturers or pharmaceuticals' (see A.F.2).
Both other stakeholders and competitors were also fre-
quently cited as critics. Stakeholders were generally per-
ceived as critics when a new technology was not
recommended (see A.F.2). Several organizations also
identified as critics those who thought the processes took
too long and cost too much and those with different
methodological viewpoints (see A.F.2).
Examples of successes and failures
Most of the examples of success among organizations pro-
ducing CPGs, HTAs, or both were occasions where there
was a perception that clinicians adhered to the organiza-
tion's recommendations or policymakers based their deci-
sions (at least in part) on the work of the organization.
Only one organization producing CPGs, HTAs, or both
could not identify an example of success, but on the other
hand only one organization cited data from an audit to
support the perception that clinicians adhered to the
organization's recommendations. In three of the exam-
ples of policymakers acting on the work of an organiza-
tion, an intervention was recommended, and
policymakers' subsequent support for the intervention
was perceived as a success (see A.F.2). In another three of
the examples of policymakers acting on the work of an
organization, an intervention was not recommended and
policymakers' subsequent lack of support for the interven-
tion was perceived as a success. One director cited a Min-
ister's decision not to start a screening program, and a
second cited a Minister's decision not to fund an expen-
sive new technology, despite lobbying. A third director
cited the example of a decision not to fund a drug and
argued that this decision had saved lives and money (see
A.F.2). Two examples of success were drawn from the field
of public health: one that addressed smoking cessation,
where success was attributed to good timing; the other
addressed lowering the legal blood alcohol level for driv-
ers.
The examples of success among GSUs were more diverse
and the pathway from research evidence to policy more
complex. Several organizations did not identify any exam-
ples of success or failure, noting that their role is only to
report the research evidence, and the decision about
whether and how to act on the research evidence is best
left to others. The examples of success again tended to rep-
resent occasions where policymakers based their decisions
(at least in part) on the work of the organization. One
director cited examples of savings and improved accessi-
bility to effective drugs from using generic drugs and sup-
porting local producers. Another director cited savings
from the discounts that could be negotiated based on drug
class reviews. Other domains where success had been
achieved included evaluations of a national health
reform, healthcare financing policies, implementation of
a human resources policy leading to re-categorising health
professionals, provision of funds by a donor agency to
support local coordination of HIV programs, and a hous-
ing policy.
The so-called failures typically involved the perception
that clinicians were not adhering to the organization's rec-
ommendations, or policymakers were not basing their
decisions (at least in part) on the work of the organiza-
tion. Reasons ranged from insufficient awareness-raising
among decision-makers to political lobbying by the
patient groups, specialists, and companies directly
affected by the decision. Often, the failures involved a
technology not being recommended, but policymakers
deciding to fund it anyway. However, one failure involved
a technology being recommended but not being funded
by government. Among the four examples of failures that
pertained to broader health system policies, two recom-
mendations were complex and a clear explanation was
not offered as to why they were not acted upon (even
though one would have saved the government money),
one recommendation was likely not acted on because it
was too broad, and one (involving cuts to the number of
hospitals or to the number of beds within hospitals) was
likely not acted on due to political opposition. Several
other 'problems' were noted as well, such as insufficient
research evidence, use of an intervention beyond its rec-
ommended uses, and inadequate monitoring of adher-
ence to guidelines through audit (see A.F.2).
Other strengths and weakness
When asked about any other strengths and weaknesses in
how the organizations are organized, directors repeated
many of the same strengths that were described previously
(e.g., independence, particularly from the pharmaceutical
industry, close links to decision-makers, well trained and
committed staff, use of rigorous methods, an interdiscipli-
nary, collaborative approach, stakeholder involvement,
and international collaboration), as well as many of the
same weaknesses (e.g., a lack of well trained staff, insuffi-
cient resources, inadequate international collaboration,
the amount of time, energy, and resources required, and
unrealistic expectations of clients). The relatively small
size of the organizations was viewed by many organiza-
tions either as a strength or as both a strength and a weak-
ness (see A.F.2). The relatively small size of the
organizations and the relatively low pay of those working
in the organizations were viewed by some organizations
as a weakness (see A.F.2).Implementation Science 2008, 3:55 http://www.implementationscience.com/content/3/1/55
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Advice to others
The advice offered to those trying to establish similar
organizations can be grouped into seven main recom-
mendations.
Collaborate with other organizations
Most directors emphasised collaboration as important
both in establishing an organization and in the ongoing
work of an organization (see A.F.2).
Establish strong links with policymakers and involve stakeholders in 
the work
Many directors, particularly those working in GSUs,
strongly recommended that organizations 'establish links
to policymakers' (see A.F.2). A number of directors from
across all types of organizations also stressed the impor-
tance of involving stakeholders (see A.F.2).
Be independent and manage conflicts of interest among those 
involved in the work
While many directors argued for establishing strong links
with policymakers and involving stakeholders in the
organization's work, a number of them highlighted the
importance of being independent and managing conflicts
of interest (see A.F.2).
Build capacity among those working in the organization
Many directors emphasised the challenge and the impor-
tance of recruiting or training multidisciplinary staff (see
A.F.2). A couple of directors noted the importance of hav-
ing a multidisciplinary team and, specifically in LMICs,
thinking internationally (see A.F.2). Several directors, par-
ticularly those working in GSUs, emphasised the impor-
tance of leadership capacity (see A.F.2).
Use good methods and be transparent in the work
Many directors stressed the importance of using good
methods and being transparent (see A.F.2).
Start small, have a clear audience and scope, and address important 
questions
A number of directors stressed the magnitude of the work
involved, and hence the importance of starting small, hav-
ing a clear audience and scope, and addressing important
questions (see A.F.2). And while several directors pointed
out the need to address important questions, no consist-
ent advice emerged about how to approach the selection
of questions (see A.F.2).
Be attentive to implementation considerations even if 
implementation is not a remit
Several directors noted the importance of implementation
(see A.F.2). A number of directors who did not comment
on implementation had made clear that implementation
is not part of their organizations' work; however, some of
these directors indicated that implementation considera-
tions still inform their work even if responsibility for
implementation lies elsewhere.
Roles for WHO
Only a small number of directors provided comments
about WHO's potential role. However, these comments
almost always pertained to the role that WHO is or could
be playing in fostering collaborations across organiza-
tions (see A.F.2).
Discussion
Principal findings from the interviews
The organizations employed a mix of models for produc-
ing outputs – with some undertaking some or all of the
work internally and others commissioning some or all of
the work externally – and there was substantial variation
in the number and type of activities in which the organi-
zations were involved. All but one of the organizations
producing CPGs, HTAs, or both used informal methods
for setting priorities, whereas GSUs were more likely to
respond directly to government requests. Organizations
producing CPGs, HTAs, or both were much more likely
than GSUs to conduct or use systematic reviews and to
have a manual that described the methods they use. Using
rigorous methods that are systematic and transparent
(sometimes shortened to 'being evidence-based') was the
most commonly cited strength among all organizations,
whereas organizations producing CPGs, HTAs, or both
noted inadequate resources coupled with using labour-
and time-intensive processes as weaknesses, and GSUs
noted limitations of the methods used or how the meth-
ods were employed as weaknesses.
There was a great deal of variability in who makes recom-
mendations or policy decisions related to the organiza-
tions' products, the processes they use, and the perceived
strengths and weaknesses in these processes. Several
organizations referred to the explicit use of research evi-
dence as a strength of the processes, and the time or capac-
ity needed to produce recommendations as a weakness.
GSUs more consistently described their close links with
policymakers as a strength, particularly those GSUs based
in government, whereas organizations producing CPGs,
HTAs, or both had conflicting viewpoints about such
close links. Most organizations argued that it is the clients
who requested a CPG or HTA, the minister of health or
more generally the department of health who is responsi-
ble for implementing recommendations or policy deci-
sions related to their products. With few exceptions, all
types of organizations tended to focus largely on weak-
nesses in implementation, rather than strengths. While
informal relationships with policymakers were identified
more frequently as important by GSUs than by organiza-
tions producing CPGs, HTAs, or both, nearly all of theImplementation Science 2008, 3:55 http://www.implementationscience.com/content/3/1/55
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organizations reported using personal communications
with decision-makers, particularly policymakers, and
many of the organizations viewed their close links with
policymakers as a strength. While health professionals
(particularly those involved in the organizations' activi-
ties) and policymakers were often identified as advocates,
and drug companies, patient groups, and competitors
were often identified as critics, particular sub-groups
could be supportive or critical depending on their percep-
tion of the organizations' general focus (e.g., threatening
professional freedom, diminishing the role of expertise,
creating funding pressures, and enhancing accountabil-
ity), its specific approach (e.g., including some forms of
research evidence but not others, consulting broadly with
affected groups, taking too long or charging a fee to pro-
duce a report, and producing reports that are difficult to
understand), and its specific recommendations on any
given topic (e.g., recommending against providing, cover-
ing or reimbursing a technology).
Most of the examples of success among organizations pro-
ducing CPGs, HTAs, or both were occasions where there
was a perception that clinicians adhered to the organiza-
tion's recommendations, or policymakers based their
decisions (at least in part) on the work of the organiza-
tion. The examples of so-called success among GSUs were
more diverse, and the pathway from research evidence to
policy more complex. The so-called failures typically
involved the perception that clinicians were not adhering
to the organization's recommendations, or policymakers
were not basing their decisions (at least in part) on the
work of the organization. Reasons ranged from insuffi-
cient awareness-raising among decision-makers to politi-
cal lobbying by the patient groups, specialists, and
companies directly affected by the decision. The advice
offered to those trying to establish similar organizations
can be grouped into seven main recommendations: 1)
collaborate with other organizations; 2) establish strong
links with policymakers and involve stakeholders in the
work; 3) be independent and manage conflicts of interest
among those involved in the work; 4) build capacity
among those working in the organization; 5) use good
methods and be transparent in the work; 6) start small,
have a clear audience and scope, and address important
questions; and 7) be attentive to implementation consid-
erations even if implementation is not a remit. Only a
small number of directors provided comments about
WHO's potential role, however, these comments almost
always pertained to the role that WHO (or another inter-
national organization or network) is or could be playing
in fostering collaborations across organizations.
Strengths and weaknesses of the interviews
The interviews have three main strengths: 1) we drew on
a regionally diverse project reference group to ensure that
our draft protocol and interview guide were fit for pur-
pose; 2) we interviewed roughly equal numbers of CPG-
and HTA-producing organizations and GSUs; and 3) no
organization declined to participate in the interviews. The
interviews have three main weaknesses: 1) despite signifi-
cant efforts to identify organizations in low- and middle-
income countries, just under one-half (48%) of the organ-
izations we interviewed were drawn from high-income
countries; 2) despite efforts to ask questions in neutral
ways, many organizations may have been motivated by a
desire to tell us what they thought we wanted to hear (i.e.,
there may be a social desirability bias in their responses);
and 3) given the nature of many of the structured ques-
tions posed and responses given the analysis relied heav-
ily on counting and hence could have missed subtleties in
emphasis and inadvertent omissions of select points.
What the interviews add
The findings from our interview study, the most broadly
based of its kind, extend the applicability of the messages
arising from previous interview studies of HTA agencies to
both CPG-producing organizations and GSUs. First, our
findings concur with several conclusions from an inter-
view study focused on prominent individuals associated
with HTA and health services research in Canada in 1999
[17]. The study found that: 'A key question now being
asked by policymakers – implicitly if not explicitly – con-
cerns the value for money from funding HTA organiza-
tions. Might funds not be spent better on other activities?'
Interviewees acknowledged insufficiencies in their ability
to document their value relative to their budgets. The con-
clusions that were or can be drawn from this finding sup-
port the advice to collaborate with other organizations
and, indirectly, the advice to establish strong links with
policymakers, involve stakeholders in the work, and to be
attentive to implementation considerations even if imple-
mentation is not a remit. Second, our findings concur
with two conclusions that were or can be drawn from an
interview study (which, like ours, followed a survey)
focused on European HTA agencies that participated in a
collaborative project called EUR-ASSESS [14]. The study
found a wide diversity of approaches and highlighted the
importance of collaboration and shared learning, which is
consistent with the advice to collaborate with other organ-
izations. The study also provided support for the advice to
be attentive to implementation considerations. Third, our
findings concur with four conclusions that were or can be
drawn from an interview study focused on the directors
and staff from six Canadian HTA agencies [18,20]. In
terms of the production of HTAs, the study found tensions
between: 1) standardising and streamlining production
and diversifying outputs; 2) contextualising results and
sharing work across agencies; 3) addressing a large scope
and addressing one well-delineated question; and 4)
doing more and producing less measurable outputs [18].Implementation Science 2008, 3:55 http://www.implementationscience.com/content/3/1/55
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In terms of the dissemination of HTAs, the study found
that although the HTA agencies had recognised that dis-
semination activities need to be intensified, why and how
particular approaches should be adopted was still under
debate [20]. A parallel interview study of HTA users found
that significant organizational, scientific, and material
limitations hinder the use of scientific evidence and sug-
gested that overcoming such barriers requires a greater
commitment from both HTA producers and users [19].
The conclusions that were or can be drawn from these
three related studies are consistent with the advice to col-
laborate with other organizations, to involve stakeholders
in the work, to use good methods and be transparent in
the work, and to be attentive to implementation consider-
ations. Our interview study also provides a rich descrip-
tion of the structure, processes, outputs, and perceived
strengths and weaknesses of CPG-producers and GSUs as
well as HTA-producers, which can be drawn upon by
those establishing or leading similar organizations in
LMICs.
Implications for policymakers and for international 
organizations and networks
As we argued in the first article in the series, policymakers
can play a strong supporting role for these organizations,
both by building strong links with the organizations while
respecting their independence and by encouraging them
to follow the recommendations that emerged from the
study, such as to collaborate with other organizations.
WHO and international networks such as the Guidelines
International Network and the International Network of
Agencies for Health Technology Assessment have an
important role to play in fostering collaboration among
organizations, particularly collaboration that brings
together well-established organizations with organiza-
tions that are new or have only limited capacity. The reli-
ance of many organisations (particularly those producing
CPGs and HTAs) on systematic reviews suggests that other
international networks, such as the Cochrane Collabora-
tion, have important roles to play both in conducting and
keeping up-to-date systematic reviews that address impor-
tant high-priority policy questions and in building capac-
ity to undertake systematic reviews that address such
questions.
Implications for future research
Given that timing or timeliness emerged as one of two fac-
tors that increase the prospects for research use in policy-
making, and that the labour- and time-intensiveness of
the processes used was a commonly cited weakness,
research is needed to develop methods and organizational
structures to respond rapidly to policymakers' questions
[22]. There is also a need for research about balancing the
need for strong links with policymakers on the one hand
and the need for independence and managing conflicts of
interest on the other, and for research about supporting
the use of reports and the implementation of their recom-
mendations.
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